Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 2/20 | 0.55 |
| ▸ | YAP1 | P46937 | 1/20 | 0.55 |
| ▸ | ALDH3A1 | P30838 | 3/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 10/20 | 0.38 |
| ▸ | CCR9 | P51686 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29901822 | 0.92 | TEAD1 (0.64) | TEAD1YAP1ALDH3A1TNNI3KCCR9 | |
| SCHEMBL20766874 | 0.92 | TEAD1 (0.64) | TEAD1YAP1ALDH3A1TNNI3KCCR9 | |
| SCHEMBL20766875 | 0.88 | ALDH3A1 (0.54) | TEAD1YAP1ALDH3A1TNNI3KALDH1A1 | |
| SCHEMBL20766297 | 0.85 | TEAD1 (0.49) | TEAD1YAP1ALDH3A1TNNI3KCCR9 | |
| SCHEMBL29901827 | 0.85 | TEAD1 (0.49) | TEAD1YAP1ALDH3A1TNNI3KCCR9 | |
| SCHEMBL25789954 | 0.85 | TEAD1 (0.46) | TEAD1YAP1ALDH3A1TNNI3KMAPT | |
| SCHEMBL20766627 | 0.84 | TEAD1 (0.46) | TEAD1YAP1ALDH3A1TNNI3KALDH1A1 | |
| SCHEMBL29901830 | 0.84 | TEAD1 (0.46) | TEAD1YAP1ALDH3A1TNNI3KALDH1A1 | |
| SCHEMBL25790329 | 0.84 | TEAD1 (0.41) | TEAD1YAP1CCR9ALDH1A1MAPT | |
| SCHEMBL29901803 | 0.84 | TEAD1 (0.52) | TEAD1YAP1TNNI3KCCR9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | TEAD1 1/4885YAP1 9/4885ALDH3A1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.